12:00 AM
 | 
Apr 15, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

DMUC5754A: Phase I data

An open-label, dose-escalation, U.S. Phase I trial in 44 evaluable patients with advanced recurrent platinum-resistant ovarian cancer showed that 0.3-3.2 mg/kg IV DMUC5754A every 3 weeks led to 1 complete response and 4 partial responses, plus 24 cases of stable disease. The complete and partial...

Read the full 202 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >